InVivo Therapeutics NVIV Stock
InVivo Therapeutics Price Chart
InVivo Therapeutics NVIV Financial and Trading Overview
| InVivo Therapeutics stock price | 0.32 USD |
| Previous Close | 1.12 USD |
| Open | 1.13 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 1200 |
| Day's Range | 1.12 - 1.14 USD |
| 52 Week Range | 0.81 - 7.98 USD |
| Volume | 5.55K USD |
| Avg. Volume | 15.64K USD |
| Market Cap | 3.48M USD |
| Beta (5Y Monthly) | 0.814661 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NVIV Valuation Measures
| Enterprise Value | -6491316 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.1037037 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.3004292 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.665 |
Trading Information
InVivo Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.814661 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 7.98 USD |
| 52 Week Low | 0.81 USD |
| 50-Day Moving Average | 1.22 USD |
| 200-Day Moving Average | 1.49 USD |
NVIV Share Statistics
| Avg. Volume (3 month) | 15.64K USD |
| Avg. Daily Volume (10-Days) | 7.51K USD |
| Shares Outstanding | 3.11M |
| Float | 2.77M |
| Short Ratio | 1.52 |
| % Held by Insiders | 10.73% |
| % Held by Institutions | 3.74% |
| Shares Short | 14.32K |
| Short % of Float | 0.45% |
| Short % of Shares Outstanding | 0.45% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | June 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -41.77% |
| Return on Equity (ttm) | -76.95% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -9765000 USD |
| Net Income Avi to Common (ttm) | -9385000 USD |
| Diluted EPS (ttm) | -4.23 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 10.72M USD |
| Total Cash Per Share (mrq) | 3.45 USD |
| Total Debt (mrq) | 754K USD |
| Total Debt/Equity (mrq) | 6.51 USD |
| Current Ratio (mrq) | 9.14 |
| Book Value Per Share (mrq) | 3.728 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -10216000 USD |
| Levered Free Cash Flow (ttm) | -7974500 USD |
Profile of InVivo Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | One Kendall Square |
| ZIP | 02139 |
| Phone | 617 863 5500 |
| Website | https://www.invivotherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 6 |
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Q&A For InVivo Therapeutics Stock
What is a current NVIV stock price?
InVivo Therapeutics NVIV stock price today per share is 0.32 USD.
How to purchase InVivo Therapeutics stock?
You can buy NVIV shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for InVivo Therapeutics?
The stock symbol or ticker of InVivo Therapeutics is NVIV.
Which industry does the InVivo Therapeutics company belong to?
The InVivo Therapeutics industry is Biotechnology.
How many shares does InVivo Therapeutics have in circulation?
The max supply of InVivo Therapeutics shares is 3.11M.
What is InVivo Therapeutics Price to Earnings Ratio (PE Ratio)?
InVivo Therapeutics PE Ratio is 0.00000000 now.
What was InVivo Therapeutics earnings per share over the trailing 12 months (TTM)?
InVivo Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the InVivo Therapeutics company belong to?
The InVivo Therapeutics sector is Healthcare.
InVivo Therapeutics NVIV included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}